Document is current
Any future updates will be listed below
-
Authors
Blasiak, Agata https://orcid.org/0000-0003-0727-7611
Tan, Lester W. J.
Chong, Li Ming https://orcid.org/0000-0002-3742-2704
Tadeo, Xavier https://orcid.org/0000-0003-0356-826X
Truong, Anh T. L.
Senthil Kumar, Kirthika https://orcid.org/0000-0002-6412-5879
Sapanel, Yoann https://orcid.org/0000-0001-6797-7850
Poon, Michelle
Sundar, Raghav https://orcid.org/0000-0001-9423-1368
de Mel, Sanjay
-
Funding
Funding for this research was provided by:
National Research Foundation Singapore (AISG-GC-2019-002)
MOH | National Medical Research Council (MOH-OFLCG18May-0028)
- License Information
-
More Information
Article History
Received: 22 January 2024
Accepted: 12 July 2024
First Online: 27 August 2024
Competing interests
: D.H. discloses equity in KYAN Therapeutics. R.S. discloses support from Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, Eli Lilly, Roche, AstraZeneca, DKSH, MSD, Paxman Coolers, Natera, Astellas, GSK, Ipsen outside the submitted work. S.D.M. reports roles in the Advisory board for Amgen and Pfizer, not related to the drugs discussed in this manuscript. A.B., A.T.L.T., L.W.J.T., K.S.K., S.-B.T., and D.H. are coinventors of previously filed pending patent(s) on AI–based therapy development. The remaining authors declare no competing interests.
